Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) is a biotechnology leader pioneering RNA-targeted therapies through its antisense technology platform. This news hub provides investors and industry professionals with comprehensive updates on the company's clinical developments, strategic partnerships, and regulatory milestones.
Access real-time updates on Ionis' innovative research in neurology, cardiology, and rare diseases, including progress on therapies like Qalsody and Wainua. The page aggregates essential information including earnings reports, collaboration announcements with partners such as Biogen and AstraZeneca, and clinical trial outcomes.
Our curated collection serves as your primary source for tracking Ionis' advancements in antisense oligonucleotide development and commercialization strategies. Bookmark this page for streamlined access to verified updates about licensing agreements, patent developments, and therapeutic pipeline expansions.
Ionis Pharmaceuticals announced positive topline results from its Phase 1/2a trial of ION582 for Angelman syndrome, a serious neurodevelopmental disorder. The HALOS study showed ION582 to be safe and well-tolerated, with consistent improvements across cognition, communication, and motor functions. Approximately 65-70% of patients showed improvements in key functional areas at six months. Ionis plans to advance ION582 into a pivotal trial and present detailed data at an upcoming medical meeting. However, Biogen has opted not to license ION582.
Ionis Pharmaceuticals announced it will hold its 2024 virtual Annual Meeting of Stockholders on June 6, 2024. The event will start at 5:00 p.m. ET, with stockholders of record as of April 8, 2024, invited to participate. A general corporate update, including a Q&A session, will follow at 5:30 p.m. ET, presented by CEO Brett P. Monia. Stockholders will receive proxy cards needed to log in, vote, and submit questions. Technical assistance will be available. The event will be webcast live, with an archived replay available later.
Ionis Pharmaceuticals, Inc. reported its first quarter 2024 financial results, highlighting positive Phase 3 data for HAE and regulatory submissions for olezarsen. The company remains on track to achieve its 2024 financial guidance, with revenue totaling $119 million and operating expenses increasing due to strategic investments in new products. Ionis' cash and short-term investments stand at $2.2 billion, supporting planned upcoming launches and reaffirmed financial guidance.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
